meningitis group A C Y and W-135 vaccine (Rx) - Menactra, Menomune A/C/Y/W-135, more..Menveo

vaccine

• 0.5mL/vial

Adults <55 years (persistent complement deficiency or asplenia)

• Conjugated vaccine (Menactra, Menveo) recommended for aged 2-55 yr
• 2-dose primary series administered 2 months apart for persons aged 2 through 54 years with persistent complement component deficiency (eg, C5-C9, properidin, factor H, or factor D) and functional or anatomic asplenia, and for adolescents with human immunodeficiency virus (HIV) infection
• Primary series (2 doses): 0.5 mL IM, then repeat in 2 months
• Booster dose: 0.5 mL IM every 5 years
• If 1-dose primary series was administered, give booster dose at earliest opportunity, then every 5 years

CDC recommends for

• People with anatomic or functional asplenia
• Microbiologists exposed to Neisseria meningitidis
• Military recruits
• People with terminal complement component deficiencies
• Travelers to and US citizens residing in sub-Saharan Africa
• Required by Saudi Arabia for all travelers to Mecca during annual Haji
• College freshmen up to 21 years old residing in dormitories if they have not received a dose on or after their 16th birthday

Revaccination

• Every 5 years for adults previously vaccinated with MCV4 or MPSV4 who remain at increased risk for infection (eg, adults with anatomic or functional asplenia or persistent complement component deficiencies)
• Residing epidemic diseases areas

vaccine

• 0.5mL/vial

High risk children aged 9-23 months (Menactra)

• 0.5 mL IM; give 2 doses 3 months apart
• Risk factors include persistent complement component deficiencies (e.g., C5--C9, properdin, factor H, or factor D), children who are traveling to or residents of countries where meningococcal disease is hyperendemic or epidemic, and children who are in a defined risk group during a community or institutional meningococcal outbreak
• Booster dose: Children who received the 2-dose series at age 9-23 months and are at prolonged, increased risk should receive a booster 3 years after completing the primary series; after this initial booster, persons who remain in 1 of the increased risk groups should continue to receive a booster dose at 5-year intervals

Primary immunization

• Conjugated vaccine (Menactra, Menveo) recommended for aged 2-55 yr
• Primary immunization is typically recommended for young adolescents (aged 11-12 yr) unless high risk or outbreak requires earlier vaccination at younger age
• Routine vaccination of adolescents preferably at age 11 or 12 years: 0.5 mL IM once at age 11-12 years; administer booster dose at designated time interval
• Booster dose (1 dose): 0.5 mL IM once at age 16 years (if primary series administered at 11-12 years) or 16-18 years (if primary series administerd at 13-15 years)

Primary immunization for high risk children/adolescents

• Conjugated vaccine (Menactra, Menveo) recommended for aged 2-55 yr
• 2-dose primary series administered 2 months apart for persons aged 2 through 54 years with persistent complement component deficiency (eg, C5-C9, properidin, factor H, or factor D) and functional or anatomic asplenia, and for adolescents with human immunodeficiency virus (HIV) infection
• 2 doses; 0.5 mL IM, then repeat in 2 months; administer booster dose as designated
• Booster dose for prolonged increased risk: 0.5 mL IM 3 years after primary series for persons 2-6 years old, and after 5 years for persons 7 years or older
• Because of their high risk for invasive pneumococcal disease, children with functional or anatomic asplenia should be vaccinated with MenACWY-D beginning at age 2 years to avoid interference with the immunologic response to the infant series of PCV
• If children aged ≥2 years with functional or anatomic asplenia have not yet received all recommended doses of PCV, they should receive all recommended doses separated from MenACWY-D by at least 4 weeks

Travel to endemic/oubreak region

• 2-10 years: Travel to countries with highly endemic or epidemic disease or outbreaks: 1 dose